Valneva (VALN) Competitors

Adaptive Biotechnologies (NASDAQ:ADPT) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Does the media prefer ADPT or VALN?

In the previous week, Valneva had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Adaptive Biotechnologies. Valneva's average media sentiment score of 0.78 beat Adaptive Biotechnologies' score of 0.07 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is ADPT or VALN more profitable?

Valneva has a net margin of -15.88% compared to Valneva's net margin of -123.24%. Adaptive Biotechnologies' return on equity of -14.56% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-123.24%	-56.58%	-27.45%
Valneva	-15.88%	-14.56%	-4.78%

Do analysts prefer ADPT or VALN?

Adaptive Biotechnologies currently has a consensus price target of $6.80, indicating a potential upside of 89.42%. Valneva has a consensus price target of $21.67, indicating a potential upside of 145.10%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Valneva is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Valneva	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable valuation and earnings, ADPT or VALN?

Valneva has lower revenue, but higher earnings than Adaptive Biotechnologies. Valneva is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$170.28M	3.11	-$225.25M	-$1.49	-2.41
Valneva	$165.52M	3.72	-$109.78M	-$0.41	-21.56

Which has more volatility & risk, ADPT or VALN?

Adaptive Biotechnologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Valneva has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.

Does the MarketBeat Community believe in ADPT or VALN?

Adaptive Biotechnologies received 68 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 56.52% of users gave Adaptive Biotechnologies an outperform vote while only 52.27% of users gave Valneva an outperform vote.

Company	Underperform	Outperform
Adaptive Biotechnologies	Outperform Votes 91 56.52%	Underperform Votes 70 43.48%
Valneva	Outperform Votes 23 52.27%	Underperform Votes 21 47.73%

Do institutionals & insiders hold more shares of ADPT or VALN?

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Valneva beats Adaptive Biotechnologies on 11 of the 18 factors compared between the two stocks.